Briumvi
ublituximab
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis
Date of authorisation:
Revision: 5
Last updated:
MedicineHumanAuthorised
Vokanamet
canagliflozin
metformin
Diabetes Mellitus, Type 2
Date of authorisation:
Revision: 22
Last updated:
MedicineHumanAuthorised
Invokana
canagliflozin
Diabetes Mellitus, Type 2
Date of authorisation:
Revision: 23
Last updated:
MedicineHumanAuthorised
EMEA-001030-PIP01-10-M10 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: P/0208/2022
Route(s) of administration: Oral use
Pharmaceutical form(s):
Film-coated tablet
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-002889-PIP02-20 - paediatric investigation plan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: P/0317/2021
Route(s) of administration: Intravenous use
Pharmaceutical form(s):
Concentrate for solution for infusion
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-002889-PIP01-20 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: P/0046/2021
Route(s) of administration: Intravenous use
Pharmaceutical form(s):
Solution for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
SGLT2 inhibitors (previously canagliflozin) - referral
canagliflozin
empagliflozin
dapagliflozin
metformin
Article 20 procedures
Associated names:
Invokana
Vokanamet
Jardiance
Synjardy
Forxiga
Edistride
Xigduo
Ebymect
Status: European Commission final decision
Opinion/position date:
EC decision date:
Last updated:
ReferralHuman
SGLT2 inhibitors - referral
canagliflozin
dapagliflozin
empagliflozin
Article 20 procedures
Status: European Commission final decision
Opinion/position date:
EC decision date:
Last updated:
ReferralHuman
EMEA-001111-PIP01-10 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: P/138/2011
Route(s) of administration: Oral use
Pharmaceutical form(s):
Tablet
Decision date:
Last updated:
Compliance check: ✖
PIPHuman